For symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥70 bpm; indicated in adults unable to tolerate or with a contraindication to the use of β-blockers or in combination with β-blockers in patients inadequately controlled with an optimal β-blocker dose; and in chronic heart failure NYHA class II-IV with systolic dysfunction, in adult patients in sinus rhythm and whose heart rate is ≥75 bpm, in combination with standard therapy including β-blocker therapy or when β-blocker therapy is contraindicated or not tolerated.